Could a simple estrogen pill reveal hidden oxytocin deficiency?

NCT ID NCT07361263

First seen Feb 01, 2026 · Last updated Jun 19, 2026 · Updated 20 times

Summary

This study is testing whether taking estrogen pills (estradiol valerate or ethinylestradiol) can safely trigger the release of oxytocin, a hormone important for social bonding and childbirth. Researchers will measure oxytocin levels in 28 healthy volunteers and patients with AVP deficiency (a condition affecting water balance). The goal is to develop a new diagnostic test for oxytocin deficiency, not to treat any disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES INSIPIDUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital Basel

    RECRUITING

    Basel, 4031, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

estradiol valerate and ethinylestradiol (estrogen pills)

What this could lead to

If successful, this could lead to a safe, simple diagnostic test for oxytocin deficiency, helping doctors identify and manage this condition more accurately.

What could go wrong

This is a very early, small study (28 participants) focused on measuring hormone levels, not treating disease. The approach may not reliably stimulate oxytocin or may cause side effects from estrogen.

Conditions

The condition(s) this trial relates to.

diabetes insipidus Diabetes Insipidus, Neurogenic neurohypophyseal diabetes insipidus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.